REE Automotive Ltd., an Israeli‑incorporated electric‑vehicle technology firm, filed its 2025 Form 20‑F under U.S. GAAP to disclose a year marked by continued losses, liquidity constraints and strategic uncertainty. The company reported a net loss of $55.8 million on revenues of only $1.3 billion, a sharp decline from the $111.8 million loss in 2024. Operating expenses exceeded $90 million, driven by high R&D and SG&A costs that were partially offset by a 24% reduction in SG&A. A $15.9 million inventory write‑down and a $24.3 million long‑lived asset impairment further eroded profitability, while cash reserves fell to $14.2 million against an expiring $18 million credit facility, leaving a runway that may end mid‑2026 without additional financing or revenue growth.
The firm’s capital structure is heavily weighted toward convertible notes and warrants, with Level 3 fair‑value liabilities totaling $1.12 million in derivatives and $2.68 million in warrants, reflecting significant fair‑value volatility. Management has raised equity through multiple public and private placements—$44.9 million in September 2024, $27.1 million in March 2025—yet still faces substantial going‑concern doubts.
Strategic risks are concentrated in supply‑chain disruptions, tariff uncertainty, and the unproven “software‑defined vehicle” (SDV) business model. Production of the P7 truck line was paused in May 2025, and future revenue hinges on securing design wins, regulatory approvals, and OEM licensing agreements. The company’s dual‑class share structure concentrates voting power with founders, potentially limiting shareholder influence.
Geographically, REE operates primarily in North America and Europe, with revenue concentrated in Germany (≈$801 k) and Japan (≈$408 k), while U.S. sales are minimal. The firm’s exposure to Israeli geopolitical instability, U.S. tax implications under Section 7874 and potential PFIC status adds further complexity to its financial outlook. Overall, REE remains in a precarious position, requiring immediate capital infusion and successful execution of its SDV strategy to avoid default or delisting.